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MaBACKGROUND The 2013 American College of Cardiology/American Heart Association updated cholesterol guidelines
recommend the use of Pooled Cohort Equations to estimate 10-year absolute risk for atherosclerotic cardiovascular
disease (ASCVD) in primary prevention.
OBJECTIVES This study sought to systematically examine the Pooled Cohort Equations to determine risk factor levels
required to exceed risk thresholds outlined in new cholesterol guidelines.
METHODS We entered continuous risk factor levels in isolation and in speciﬁed combinations with the risk tool, and we
observed predicted risk output patterns. We used the 10-year ASCVD risk threshold of $7.5% as a clinically relevant risk
threshold.
RESULTS Wedemonstrated that a hypotheticalman orwoman can reach clinically relevant risk thresholds throughout the
eligible age spectrum of 40 to 79 years of age, depending on the associated risk factor burden in all race-sex groups. Age
continues to be a major determinant of 10-year ASCVD risk for both men and women. Compared with the previous risk
assessment tool used in cholesterol guidelines, the inclusion of a stroke endpoint and use of race-speciﬁc coefﬁcients permit
identiﬁcation of at-risk African Americans and non-Hispanicwhitewomen atmuch younger ages and lower risk factor levels.
CONCLUSIONS These data provide context of speciﬁc risk factor levels and groups of individuals who are likely to have
10-year ASCVD risk estimates $7.5%. Age continues to be a major driver of risk, which highlights the importance of the
clinician-patient discussion before statin therapy is initiated. (J Am Coll Cardiol 2014;64:959–68) © 2014 by the
American College of Cardiology Foundation.I n November 2013, the American College of Cardi-ology (ACC) and American Heart Association(AHA) released updated clinical practice guide-
lines for the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular disease (ASCVD) risk
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ABBR EV I A T I ON S
AND ACRONYMS
ASCVD = atherosclerotic
cardiovascular disease
ATP III = Adult Treatment
Panel III report
CHD = coronary heart disease
CVD = cardiovascular disease
HDL-C = high-density
lipoprotein cholesterol
NHANES = National Health and
Nutrition Examination Surveys
SBP = systolic blood pressure
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960a novel risk assessment tool, developed by
the ACC/AHA Risk Assessment Work Group,
called the Pooled Cohort Equations to estimate
10-year ASCVD risk (2). In the primary preven-
tion subset, the cholesterol guidelines provide
a strong recommendation (Class I, Level of Ev-
idence: A) for consideration of statin treat-
ment in individuals with a 10-year ASCVD
risk $7.5% and a moderate recommendation
(Class IIa, Level of Evidence: B) in individuals
with a 10-year ASCVD risk of 5% to <7.5%.
The guidelines then advise clinicians to
engage in a clinician-patient discussion to
individualize the decision to initiate statintreatment on the basis of patient preferences and the
potential for ASCVD risk reduction, adverse effects,
and drug-drug interactions.SEE PAGE 969Although the Pooled Cohort Equations use many
of the same covariates included in the ATP III risk
calculator to quantitatively assess risk, the equations
represent a departure from the previous tool. On the
basis of recommendations from the AHA and the
American Stroke Association, the Pooled Cohort
Equations expand the endpoint for prediction to
ASCVD to include fatal and nonfatal stroke (3).
Moreover, diabetes is added as a predictor variable to
allow risk stratiﬁcation in the growing diabetic pop-
ulation. Additionally, the equations are derived from
pooled data from racially and geographically diverse
community-based cohorts, which permits the crea-
tion of sex- and race-speciﬁc equations for non-
Hispanic white and African-American women and
men (2).
We have previously investigated the intrinsic
properties of Framingham-derived risk scores used
in general practice (4,5). This work highlighted
inherent limitations of these risk scores and the
tendency to classify younger individuals and women
with high risk factor burden as having “low” 10-year
predicted risk. With the recent update in the
cholesterol guidelines, a revised risk threshold, and
the publication of the Pooled Cohort Equations, we
sought to examine the intrinsic properties of the
new risk assessment tool to better understand how it
may guide quantitative risk assessment in primary
prevention. Therefore, the objective of this study is
to systematically evaluate the Pooled Cohort Equa-
tions using a previously published algorithm to
determine the risk factor combinations and risk
factor levels that are required to exceed treatment
consideration thresholds in different age, sex, and
race groups.METHODS
The Pooled Cohort Equations are sex- and race-
speciﬁc risk prediction models that incorporate age,
total and high-density lipoprotein (HDL) cholesterol
levels, systolic blood pressure (SBP), use of antihy-
pertensive medication, smoking status, and diabetes
status into multivariable Cox proportional hazards
regression equations to estimate the 10-year absolute
risk for ASCVD (includes nonfatal myocardial infarc-
tion, nonfatal stroke, and fatal cardiovascular disease
[CVD]) (2). The model is based on pooled data from
several contemporary National Heart, Lung, and
Blood Institute–sponsored cohort studies, such as the
ARIC (Atherosclerosis Risk in Communities) study (6),
the CHS (Cardiovascular Health Study) (7), and the
CARDIA (Coronary Artery Risk Development in Young
Adults) study (8), combined with applicable data from
the Framingham Original (9) and Offspring Study (10)
cohorts. In total, the equations were derived from
9,098 non-Hispanic white men (1,259 events), 1,647
African-American men (238 events), 11,240 non-
Hispanic white women (902 ASCVD events), and
2,641 African-American women (290 events) between
40 and 79 years of age who were free of a previous
history of myocardial infarction (recognized or un-
recognized), stroke, congestive heart failure, percu-
taneous coronary intervention, coronary bypass
surgery, or atrial ﬁbrillation.
We downloaded an online spreadsheet of the
Pooled Cohort Equations, incorporating the sex- and
race-speciﬁc equations (11). We entered data directly
into the spreadsheet for a hypothetical non-Hispanic
white man, African-American man, non-Hispanic
white woman, and African-American woman from
40 to 79 years of age in 5-year increments. This
approach does not examine risks for speciﬁc in-
dividuals or a speciﬁc population; rather, it system-
atically varies individual risk factors and aggregate
risk factor burden to examine the effect on estimated
10-year ASCVD risk. We gave special attention to
estimated 10-year risk $7.5% because this is the
threshold delineated in the cholesterol guidelines
with a Class I recommendation to mark the point at
which the use of a statin is recommended, because
ASCVD risk reduction with a statin exceeds the risk of
adverse events as reported in clinical trials.
RISK CALCULATION PROCEDURE FOR SINGLE RISK
FACTORS. We varied single risk factor levels in
isolation, holding other risk factor levels constant at
age-adjusted national mean values, to compare the
effects of individual risk factor levels on 10-year
predicted risk for a non-Hispanic white man,
TABLE 1 Age-Adjusted Mean National Levels for Cholesterol and SBP by Race-Sex Group
Men Women
Non-Hispanic
White Men
African-American
Men
Non-Hispanic
White Women
African-American
Women
Total cholesterol, mg/dl 193 (191-195) 191 (188-193) 200 (198-202) 192 (190-194)
HDL cholesterol, mg/dl 46.7 (45.8-47.5) 52.6 (51.6-53.6) 58.1 (56.8-59.4) 58.7 (57.2-60.2)
SBP for ages 18–39 yrs,
mm Hg
118 (0.4) 121 (0.4) 109 (0.3) 114 (0.5)
SBP for ages 40–59 yrs,
mm Hg
124 (0.5) 129 (0.8) 120 (0.5) 128 (0.9)
SBP for ages $60 yrs,
mm Hg
132 (0.6) 137 (0.9) 138 (0.6) 144 (1.2)
Treated SBP for ages
18–39 yrs, mm Hg
126 (1.7) 130 (2.7) 119 (2.4) 129 (2.9)
Treated SBP for ages
40–59 yrs, mm Hg
128 (0.9) 135 (1.6) 127 (1.1) 133 (1.3)
Treated SBP for ages
$60 yrs, mm Hg
134 (0.7) 138 (1.2) 141 (0.8) 144 (1.3)
Values are mean (95% conﬁdence interval) from Carrol et al. (13) or mean (standard error) fromWright et al. (12).
HDL ¼ high-density lipoprotein; SBP ¼ systolic blood pressure.
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961African-American man, non-Hispanic white woman,
and an African-American woman. Age-adjusted
national mean values derived from published ana-
lyses from the National Health and Nutrition Exami-
nation Surveys (NHANES) are shown in Table 1 (12,13).
We used age-speciﬁc blood pressure values to reﬂect
the normative aging process seen with blood pressure
and different mean SBP values for those who
were treated and not treated with antihypertensive
medications. For these analyses, we used non-
smoking and nondiabetic status, because they are
normative values in the population. Using the entire
range of values permitted by the risk assessment tool,
we varied total cholesterol from 130 to 320 mg/dl in
increments of 10 mg/dl, HDL cholesterol from 20 to
100 mg/dl in increments of 5 mg/dl, and SBP from
90 to 200 mm Hg in increments of 10 mm Hg. We
also compared the estimated 10-year risks for
smokers (versus nonsmokers) and diabetics (versus
nondiabetics), holding all other risk factors constant
at age-adjusted national mean values for each race-
sex group. For all analyses, we calculated separate
10-year risk estimates for those with and without
antihypertensive therapy. For example, to determine
the effect of total cholesterol on 10-year ASCVD risk in
a 55-year-old non-Hispanic white woman with treated
hypertension, we selected appropriate demographic
parameters and set HDL cholesterol at 58 mg/dl, SBP
at 127 mm Hg, “yes” to antihypertensive therapy, and
“no” to smoking and diabetes status. We then varied
total cholesterol from 130 to 320 mg/dl and recorded
10-year predicted ASCVD risk estimates.
RISK CALCULATION PROCEDURE FOR MULTIPLE
RISK FACTORS. We varied the levels of all the risk
factors to values around national mean levels to
examine the effects of different risk factor combi-
nations on 10-year estimated ASCVD risk. We chose
ranges to be inclusive of a low value and a modestly
abnormal value at intervals roughly equal to 1 SD in
the population of U.S. adults. For total cholesterol,
we included values of 160 mg/dl (z1 SD below the
mean), 200 mg/dl (approximate national mean), and
240 mg/dl (z1 SD above the mean). For each race-sex
group, we used the appropriate mean HDL cholesterol
level 10 mg/dl. For SBP, we used 110 mm Hg, 130
mm Hg, and 150 mm Hg. We also varied smoking
status, diabetes status, and antihypertensive therapy
use for all risk factor combinations. We examined the
results for ages 40 to 75 years in 5-year intervals but
only graphically display the results for 50-year-old
men and 60-year-old women. These ages were chosen
because it was thought that they would offer the most
representative patterns of predicted risk factorcombinations without an undue inﬂuence of age,
with the understanding that absolute predicted risks
vary directly and substantially with age.
RESULTS
EFFECT OF VARYING AGE WITH OTHER RISK
FACTORS HELD CONSTANT AT NATIONAL MEAN
LEVELS. When we held all risk factors constant at
the age-adjusted national mean level for each race-
sex group, the 10-year predicted ASCVD risk was
substantially greater with increasing age (Central
Illustration). From 40 to 55 years of age, predicted
ASCVD risk was greatest in an African-American
man, followed by a non-Hispanic white man, an
African-American woman, and a non-Hispanic white
woman. After 60 years of age, a non-Hispanic white
man tended to have the highest 10-year ASCVD risk,
followed by an African-American woman, a non-
Hispanic white woman, and an African-American
man. There was an accelerated predicted ASCVD
risk after 60 years of age, which was in part an
artifact explained by the use of age-speciﬁc SBP
values in our model.
A non-Hispanic white man with average risk factor
levels exceeded the 7.5% 10-year ASCVD risk threshold
after 60 years of age, regardless of hypertension
treatment status. An African-American man with
average risk factor levels exceeded the 7.5% 10-year
ASCVD risk threshold after 50 years of age, if his
blood pressure was treated, and after 60 years of age
if not treated. A non-Hispanic white woman with
average risk factor levels exceeded the 7.5% ASCVD
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CENTRAL ILLUSTRATION 10-Year ASCVD Risk by Race-Sex Group
Ten-year predicted risk for atherosclerotic cardiovascular disease (ASCVD) for a hypothetical non-Hispanic white man, African-American man,
non-Hispanic white woman, and African-American woman at selected ages, with risk factors held constant at approximate age-adjusted
national means (including nondiabetic, nonsmoking). (A) Ten-year ASCVD risk estimates for those not taking antihypertensive medications.
(B) Ten-year ASCVD risk estimates for those taking antihypertensive medications. BP ¼ blood pressure.
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962risk threshold after 65 years of age if she had treated
blood pressure and after 70 years of age of age if not
treated. An African-American woman with average
risk factor levels exceeded the 7.5% 10-year ASCVD
risk threshold after 60 years of age if she had treated
blood pressure and 65 years of age if not treated.
EFFECT OF VARYING SINGLE RISK FACTORS WITH
OTHERS HELD CONSTANT AT NATIONAL MEAN
LEVELS FOR DIFFERENT AGES. Ten-year ASCVD
risks estimated after we individually varied total
cholesterol, HDL cholesterol, untreated SBP, or
treated SBP with all other risk factors held at
age-adjusted mean levels for selected ages are shown
in Figures 1 and 2 (all ages entered are included in
Online Figures 1 and 2). Ten-year risk varied linearly
with total cholesterol, untreated SBP, and treated SBP
variations in all race-sex groups. Linear variation was
modest for total cholesterol and more prominent for
untreated and treated SBP. Risk varied curvilinearly
with HDL cholesterol for all ages in a non-Hispanic
white man and an African-American man (Figures 1B
and 1F) but only up to 70 years of age for a
non-Hispanic white woman and 60 years of age for
an African-American woman (Figures 2B and 2F). After
these ages, risk estimates in women appeared to
converge, which reﬂects interaction terms within the
model or lack of data at the extremes of age and HDL
cholesterol levels. In a hypothetical man who was a
nonsmoker and did not have diabetes, 10-yearestimated ASCVD risk exceeded 7.5% at every level
entered for total cholesterol, HDL cholesterol, and
treated SBP after 65 years of age regardless of race.
In a similar hypothetical woman, this occurred at
75 years of age regardless of race.
EFFECT OF SMOKING OR DIABETES STATUS ON
ESTIMATED 10-YEAR ASCVD RISK. Smoking and
diabetes both had prominent effects on 10-year risk
of ASCVD in all race-sex groups. In a hypothetical
man with average risk factor levels and untreated
SBP, the presence of smoking or diabetes led to a
10-year estimated ASCVD risk $7.5% at 55 years of
age for a non-Hispanic white man or 45 years of age
for an African-American man (50 years of age and
40 years of age, respectively, if there was treated
SBP). In a hypothetical woman with average risk
factor levels, the presence of smoking or diabetes led
to a 10-year predicted risk $7.5% at 60 years of age for
a non-Hispanic white woman and 60 years of age for
an African-American woman (60 years of age and 50
years of age, respectively, if there was treated SBP). In
all 4 race-sex groups, the presence of diabetes
appeared to have a slightly more prominent effect on
predicted risk than smoking. The effect of diabetes
status on 10-year predicted risk is demonstrated in
Figure 3.
EFFECT OF VARYING MULTIPLE RISK FACTORS
SIMULTANEOUSLY. Ten-year ASCVD risk with vary-
ing levels of risk factors (but no antihypertensive use)
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FIGURE 1 10-Year ASCVD Risk by Varying Single Risk Factor Levels in Men
Ten-year predicted risks for atherosclerotic cardiovascular disease (ASCVD) by varying
levels of single risk factors in a hypothetical non-Hispanic white man (A to D) and African-
American man (E to H) at selected ages, with other risk factors held constant at
approximate age-adjusted national means (including nondiabetic and nonsmoking).
HDL ¼ high-density lipoprotein; SBP ¼ systolic blood pressure.
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963is demonstrated for a hypothetical 50-year-old man
in Figure 4 and a 60-year-old woman in Figure 5 for
each race category. For the risk factor levels
we entered, the range of estimated risk for a hypo-
thetical 50-year-old non-Hispanic white man was
1.7% to 30.5% in a diabetic smoker (reaching
34.9% if SBP was treated and uncontrolled) and
3.5% to 23.3% (reaching 36.4% if SBP was treated
and uncontrolled) for an African-American man.
For a hypothetical 60-year-old non-Hispanic white
woman, estimated 10-year risk was 1.8% to 21.3%
(reaching 27.9% if SBP was treated and uncontrolled)
and 2.4% to 39.7% (reaching 49.4% if SBP was
treated and uncontrolled) for an African-American
woman.
If all “low” risk factors were entered (indicated by
total cholesterol of 160 mg/dl; HDL cholesterol of 57
mg/dl for a non-Hispanic white man, 63 mg/dl for
an African-American man, 68 mg/dl for a non-
Hispanic white woman, or 69 mg/dl for an African-
American woman; and untreated SBP of 110 mm Hg)
and there was no smoking or diabetes, the 10-year
ASCVD risk threshold of $7.5% was reached at
65 years of age in a non-Hispanic white man,
70 years of age in an African-American man,
75 years of age in a non-Hispanic white woman, and
70 years of age in an African-American woman. If
“modestly abnormal” risk factor levels were entered
(indicated by total cholesterol of 240 mg/dl; HDL
cholesterol of 37 mg/dl for a non-Hispanic white
man, 43 mg/dl for an African-American man, 48
mg/dl for a non-Hispanic white woman, or 49 mg/dl
for an African-American woman; and untreated SBP
of 150 mm Hg) and there was no smoking or dia-
betes, 10-year ASCVD risk $7.5% was reached at
50 years of age for both a non-Hispanic white man
and an African-American man, 65 years of age for a
non-Hispanic white woman, and 60 years of age
for an African-American woman. Because of the
strong relationship between age and estimated risk,
younger adults with these same abnormal values for
major risk factors were estimated to be at lower
10-year ASCVD risk. With the same risk factor com-
binations plus the addition of diabetes or smoking,
the 7.5% risk threshold was reached at younger ages
for all race-sex groups.
If all “optimal” risk factor levels, as deﬁned by the
ACC/AHA Prevention Guidelines panel (total choles-
terol 170 mg/dl, HDL 50 mg/dl, untreated SBP of 110
mm Hg, and no diabetes or smoking) (1), were entered
into the risk calculator, the 10-year ASCVD risk
threshold of 7.5% was reached at 65 years of age for a
non-Hispanic white man, 70 years of age for an
African-American man, 75 years of age for anon-Hispanic white woman, and 70 years of age for an
African-American woman.
For a 40-year-old, the full range of predicted
10-year ASCVD risk with the risk factor levels we
entered was 0.4% to 22.5% for a non-Hispanic
white man, 2.1% to 23% for an African-American
man, 0.2% to 15.3% for a non-Hispanic white
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FIGURE 2 10-Year ASCVD Risk by Varying Single Risk Factor Levels in Women
Ten-year predicted risks for ASCVD by varying levels of single risk factors in a hypothetical
non-Hispanic white woman (A to D) and African-American woman (E to H) at selected
ages, with other risk factors held constant at approximate age-adjusted national means
(including nondiabetic and nonsmoking). Abbreviations as in Figure 1.
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964woman, and 0.1% to 23.5% for an African-American
woman. For a 75-year-old, the full range of pre-
dicted 10-year ASCVD risk with the risk factor levels
we entered was 17.5% to 67% for a non-Hispanic
white man, 9.3% to 70.9% for an African-American
man, 12% to 61% for a non-Hispanic white
woman, and 11.8% to 71.2% for an African-American
woman.DISCUSSION
In this study, we systematically evaluated the
intrinsic properties of the 2013 ACC/AHA Pooled
Cohort Equations under various risk factor combina-
tions and levels. We demonstrated that a hypothetical
man and woman could reach a clinically relevant 10-
year risk threshold of $7.5% throughout the eligible
age spectrum of 40 to 79 years of age, depending on
the associated risk factor burden. Three key obser-
vations stand out in our analyses. First, there were
important race-sex interactions with risk factor levels
that reﬂected differential risk for ASCVD events,
which may be particularly notable given the inclusion
of fatal and nonfatal stroke in the endpoint. Second,
the inclusion of diabetes in the equations led to
important differences in predicted risk that could
inﬂuence decision making in younger people with
diabetes. Finally, age remained a major driver of
predicted 10-year risk in the new equations, which
highlights the importance of the clinician-patient
discussion before the initiation of statin therapy,
especially for those uncommon individuals whose
sole risk factor is advanced age.
The Pooled Cohort Equations share many features
with the ATP III risk assessment tool used in prior
cholesterol guidelines, such as use of traditional
covariates (age, sex, smoking, SBP, total cholesterol,
HDL cholesterol, and antihypertensive medication
use) and estimation of CVD risk over a 10-year time
frame. However, unlike the ATP III risk calculator,
this equation also includes diabetes as a predictor
variable, expands the prediction endpoint to include
fatal and nonfatal stroke, and is derived from a
racially and geographically diverse sample, which
permits the development of sex- and race-speciﬁc
equations for non-Hispanic white and African-
American men and women. These changes modify
quantitative risk estimation particularly in African
Americans, as well as in non-Hispanic white women,
for whom risk for stroke increases earlier in life than
risk for CHD (14).
CLINICAL IMPLICATIONS. Our previous evaluation
of the intrinsic properties of the ATP III risk calcu-
lator demonstrated that few women exceeded
treatment thresholds set by ATP III guidelines when
a risk calculator that predicted a CHD endpoint was
used (4). For example, with ATP III, a nondiabetic
man with average risk factor levels could reach the
10% intermediate-risk category over 60 years of age.
A woman, however, remained in a low-risk category
at all eligible ages. Moreover, unlike a man, who
could exceed the 10% intermediate-risk threshold
with modestly elevated risk factors at 45 years of
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FIGURE 3 10-Year ASCVD Risk in Diabetic Patients by Race-Sex Group
Ten-year predicted risk for atherosclerotic cardiovascular disease (ASCVD) for a hypo-
thetical non-Hispanic white man, African-American man, non-Hispanic white woman, and
African-American woman with diabetes at selected ages, with risk factors held constant at
approximate age-adjusted national means (including nonsmoking). (A) Ten-year ASCVD
risk estimates for those not taking antihypertensive medications. (B) Ten-year ASCVD risk
estimates for those taking antihypertensive medications. BP ¼ blood pressure.
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965age, a woman could only reach this risk threshold
with extreme risk factor levels after 70 years of age
(4). Thus, per ATP III guidelines, few women quali-
ﬁed for intensive CVD prevention when ATP III
treatment thresholds were imposed on the ATP III
risk calculator to guide treatment. The inclusion of
stroke in the new Pooled Cohort Equations and the
emphasis on absolute risk, independent of low-
density lipoprotein cholesterol targets, results in
the identiﬁcation of many more women who may
beneﬁt from consideration of statin treatment.
Because stroke constitutes a much greater propor-
tion of CVD events in women (many of whom
are younger than 75 years of age) (14), these changes
in risk assessment may hold important public health
implications.
Racial disparities in CVD risk between African
Americans and non-Hispanic whites are well estab-
lished. In nearly every age group, but particularly
among those <65 years of age, incident risk for CHD
and stroke is higher among African Americans than
among non-Hispanic whites (15). Moreover, incident
CVD events are more likely to be fatal in African
Americans than in non-Hispanic whites (16,17).
In the REGARDS (Reasons for Geographic and
Racial Differences in Stroke) study, the black/white
mortality ratio for stroke was 3.7 in men 45 to
54 years of age (16). The creation of race-speciﬁc
risk equations now allows recognition and quantiﬁ-
cation of the different risk proﬁles and potential
for beneﬁt in African-American individuals com-
pared with non-Hispanic whites, particularly at
younger ages.
Among those with risk factor levels at national
mean values, our results revealed that estimated 10-
year ASCVD risk was greater in an African-American
man than in other race-sex groups from 40 to 55
years of age, regardless of blood pressure treatment,
presence of diabetes, or smoking status. As has been
demonstrated previously, a portion of this increased
risk is due to a higher prevalence of traditional risk
factors, such as hypertension (as reﬂected by the
mean SBP levels used in our calculations) and dia-
betes (18–20). However, it also highlights the poten-
tial beneﬁt of identifying this higher-risk group and
controlling these elevated risk factors in primary
prevention to reduce the incidence of future CVD
events.
The incorporation of diabetes into quantitative
risk assessment is another shift from ATP III, in
which diabetes was considered a “risk equivalent”
condition. Subsequent studies, including a system-
atic review, have demonstrated that CHD risk for
people with diabetes in primary prevention is notequivalent to the risk seen for individuals with prior
CHD events and have suggested that the diabetic
population may beneﬁt from further risk stratiﬁca-
tion (21). In our evaluation of people with diabetes,
a nonsmoking, non-Hispanic white man #50 years of
age, an African-American man #40 years of age, a
non-Hispanic white woman #60 years of age, and an
African-American woman #55 years of age with
otherwise average risk factor levels could have an
estimated 10-year ASCVD risk <7.5%. This means
clinicians can discuss the relative merits of statin
treatment on an individual basis with younger peo-
ple who have diabetes. Nevertheless, diabetes re-
mains a major risk factor for CVD, and the presence
of diabetes increases predicted 10-year ASCVD risk in
all race-sex groups. For example, 60 years of age in a
non-Hispanic white man, 55 years of age in an
African-American man, or 70 years of age in a woman
(regardless of race), nearly all people with diabetes,
even those with the low risk factor levels, exceed the
7.5% 10-year risk threshold.
The strong age effect on 10-year multivariable risk
assessment was once again demonstrated. Even
among individuals with optimal risk factors, 10-year
ASCVD risk $7.5% was reached by 65 years of age
in a non-Hispanic white man, 70 years of age in an
African-American man, 75 years of age in a non-
Hispanic white woman, and 70 years of age in an
African-American woman. Unfortunately, very few
individuals with all optimal risk factors actually exist
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FIGURE 4 10-Year ASCVD Risk by Varying Multiple Risk Factors at 50 Years of Age in Men
Ten-year predicted risk for ASCVD by varying levels of multiple risk factors in a hypothetical non-Hispanic white man (A) and African-American
man (B) at 50 years of age. HDL-c ¼ high-density lipoprotein cholesterol; other abbreviations as in Figure 1.
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966in the United States, as data from National Health
and Nutrition Examination Surveys (NHANES) esti-
mate a prevalence of 2.4% of all optimal risk factors
in U.S. adults $60 years of age (15). A brief analysis
of NHANES from 2007 to 2010 among non-pregnant
participants 40 to 79 years of age without prevalent
CVD revealed a prevalence of optimal risk factors of
only 4.9% in all adults 40 to 79 years of age. Among
non-Hispanic white men $65 years of age, theprevalence of all optimal risk factors was 5.8%, and
among non-Hispanic white women $75 years of age,
the prevalence of all optimal risk factors was 2.4%.
Within the NHANES dataset, there were no African-
American men or women who had all optimal risk
factors. Thus, the clinical and public health signiﬁ-
cance of this feature of the equations is minimal.
From a clinical perspective, the recommended
clinician-patient discussion should facilitate shared
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FIGURE 5 10-Year ASCVD Risk by Varying Multiple Risk Factors at 60 Years of Age in Women
Ten-year predicted risk for ASCVD by varying levels of multiple risk factors in a hypothetical non-Hispanic white woman (A) and
African-American woman (B) at 60 years of age. Abbreviations as in Figures 1 and 4.
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967decision making regarding the potential use of sta-
tins in these individuals with optimal risk factors.
Conversely, young individuals 40 to 50 years of age
may not reach a 10-year predicted ASCVD risk of
7.5% or even the moderately recommended risk
threshold of 5% to <7.5% 10-year ASCVD risk in spite
of signiﬁcant risk factor burden. These ﬁndings
highlight the importance of engaging in a clinician-
patient discussion before statin prescription to re-
view the speciﬁc components that contribute to the
patient’s CVD risk and potential modiﬁable factorsthat could mitigate that risk. They also underscore
the importance of the recommendation to assess
longer-term risk in younger individuals (age
#50 years of age) who may have substantial risk
factor burden but low short-term risk, primarily
because of their age.
STUDY LIMITATIONS. The precision of our ﬁndings is
limited by the increments of age and risk factor levels
that were used. We also varied a single risk factor at a
time to illustrate the impact of the particular risk
factor on predicted 10-year ASCVD risk. However, we
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
2013 American College of Cardiology/American Heart
Association guidelines on management of blood
cholesterol recommend new Pooled Cohort Equations
to estimate a patient’s 10-year risk of atherosclerotic
cardiovascular disease for primary prevention.
TRANSLATIONAL OUTLOOK: The effectiveness of
guiding cardiovascular disease prevention on the basis
of estimated absolute risk needs veriﬁcation in pro-
spective studies.
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968acknowledge that many risk factors are correlated
and that some of our combinations would be rare
in the general population. Although the Pooled
Cohort Equations were derived from a more contem-
porary and diverse population than the previous
Framingham-derived ATP III risk tool, the accuracy of
current estimates is still limited by the relatively
small numbers of African Americans included in the
cohorts and secular trends of declining ASCVD inci-
dence, which may lead to overestimation of risk.
CONCLUSIONS
The updated ACC/AHA cholesterol guidelines
recommend the use of newly derived Pooled Cohort
Equations to estimate 10-year ASCVD risk. The pre-
sent study provides context of speciﬁc risk factor
levels and groups of individuals who are likely to
have 10-year ASCVD risk estimates exceeding 7.5%.
Compared with the ATP III risk assessment tool, the
inclusion of stroke endpoints and use of race-speciﬁc
coefﬁcients permits identiﬁcation of at-risk women
and African Americans at much younger ages and at
lower risk factor levels. Age continues to be a majordriver of 10-year ASCVD risk, which highlights the
importance of the clinician-patient discussion before
initiation of statin therapy.
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